- Supported exchanges /
- TWO /
- 6589.TWO
EirGenix (6589 TWO) stock market data APIs
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. EirGenix Inc. was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
EirGenix Financial Data Overview
83 | |
83.3 | |
- | |
83.9 | |
83 | |
72.2-111 | |
25 416 M | |
306 M | |
1 134 M | |
-0.72 | |
0.62 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
EirGenix Fundamental Data is available in our Financial Data APIs
- Net Revenue 1 134 M
- EBITDA -788 576 000
- Earnings Per Share -2.75
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get EirGenix Earnings via APIs
- Latest Release 2024-08-08
- EPS/Forecast -0.42
Get EirGenix End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: